Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysis.

GBA1 变异体的分类及其对帕金森病的影响:计算机评分分析

阅读:9
作者:Lanore Aymeric, Tesson Christelle, Basset Aymeric, Lejeune François-Xavier, Cogan Guillaume, Mangone Graziella, Sambin Sara, Bertille Nathalie, Anheim Mathieu, Arnulf Isabelle, Ansquer Solène, Brandel Jean-Philippe, Brefel-Courbon Christine, Defebvre Luc, Drapier Sophie, Eusebsio Alexandre, Fabbri Margherita, Giordana Caroline, Hainque Elodie, Lehericy Stephane, Marques Ana, Moreau Caroline, Moro Elena, Ory Fabienne, Rolland Anne-Sophie, Thobois Stéphane, Vidailhet Marie, Devos David, Mariani Louise-Laure, Lesage Suzanne, Brice Alexis, Corvol Jean-Christophe
Bi-allelic pathogenic GBA1 variants cause Gaucher disease (GD), whereas certain heterozygous missense variants increase the risk of Parkinson's disease (PD), although the underlying mechanisms are unclear. Here, we classified GBA1 missense variants using predictive and structural scores, and analysed their associations with enzyme activity, Saposin C (SapC) interaction and PD progression in 639 patients with heterozygous GBA1 variants from five cohorts. Principal component analysis (PCA) identified two components: PC1, associated with reduced β-glucocerebosidase activity, the GD clinical severity classification, younger age at PD diagnosis, and faster cognitive and motor decline; and PC2, associated with surface-exposed, flexible regions involved in SapC interactions, younger age at PD diagnosis, and slightly with motor decline. These findings highlight that impaired SapC interactions, in addition to reduced activity, may contribute to PD severity in GBA1 variant carriers. This is relevant for therapeutic approaches aimed at stabilizing β-glucocerebosidase or enhancing its enzymatic activity in PD.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。